RxDoctor Payments DataLook up a doctor →

Corey Hunter, MD

Interventional Pain Medicine · New York, NYNPI 1194999532

Payments from drug & device makers

$571,040in general payments, 2019–2025

Across 700 payments — averaging $815.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$341K
  • Saluda Medical Americas, Inc.$70K
  • Nalu Medical, Inc.$50K
  • MML US, Inc.$38K
  • Vertiflex, Inc.$33K
  • Biotronik Inc.$9K
  • plus $31K from 23 others
$70,283in research payments, 2019–2025

Across 298 payments — averaging $235.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$27K
  • Abbott$22K
  • MML US, Inc.$18K
  • Saluda Medical Americas, Inc.$4K

What the payments were for

  • Consulting fees$135,81030%
  • Speaking & faculty fees$206,15246%
  • Travel & lodging$43,30010%
  • Food & beverage$16,0254%
  • Ownership interest$42,87910%
  • Other$2,1540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$571,040 in reported general payments places this provider in the 95th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$238,919
Medicare patients
105
Services billed
5,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin25$51
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$32

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →